You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》匯豐研究上調中生製藥(01177.HK)目標價至9.4元重申「買入」評級
阿思達克 06-25 15:03

匯豐研究發表報告,指出踏入2020年,在人口老齡化加速的背景下,患者數量將大幅增長,刺激中國的醫藥消費。另外,考慮到一系列潛在的重磅產品獲審批,對中國2020年的健康護理板塊有更積極的看法。擁有強大管道及銷售團隊的領先企業有望獲得最大優勢。

該行維持中生製藥(01177.HK)「買入」投資評級,目標價由原來的8.8元上調至9.4元。對其2019至2021年收入預測維持不變,並較行業預測分別高出9%、7%及10%,因為預期專利藥品的銷售增加,能抵銷藥品集中採購後失卻仿製藥市場份額的影響;對其2019至2020年盈利預測則分別下調6.1%及9.2%,預期公司將會繼續加大研發投入。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account